Michael L. Nicholson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Michael L. Nicholson has a total of 150 co-authors. Here are the top co-authors by number of shared publications:
- Sarah A. Hosgood
Department of Surgery, University of Cambridge, Addenbrooke’s Hospital, Cambridge, United Kingdom
26 shared publications - Sara Deffrennes
Department of Development and Regeneration, Katholieke Universiteit Leuven, Leuven, Belgium; Department of Nephrology, Dialysis and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium
4 shared publications - Serena MacMillan
Department of Surgery, University of Cambridge, Cambridge, UK
4 shared publications - Anna L. Paterson
Department of Histopathology, Addenbrooke's Hospital, Cambridge, UK
3 shared publications - John Robert Ferdinand
Molecular Immunity Unit, Department of Medicine, University of Cambridge, MRC Laboratory of Molecular Biology
3 shared publications Mekhola Hoff
Department of Surgery Addenbrooke's Hospital University of Cambridge Cambridge UK
3 shared publications
Latest Publications
- Open Access
- 22 April 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (11) , 2511-2523
A comparative analysis of acellular versus red cell-based subnormothermic machine perfusion in human kidney transplantation
- 22 April 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (11) , 2511-2523
Open AccessA comparative analysis of acellular versus red cell-based subnormothermic machine perfusion in human kidney transplantation
- Open Access
- 13 February 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (6) , 1339-1348
Inhibition of cytomegalovirus reactivation by ex vivo treatment of human kidneys with the SYN002 immunotoxin
- 13 February 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (6) , 1339-1348
Open AccessInhibition of cytomegalovirus reactivation by ex vivo treatment of human kidneys with the SYN002 immunotoxin
- Open Access
A comparative analysis of acellular versus red cell based subnormothermic machine perfusion in human kidney transplantation
Normothermic machine perfusion (NMP) typically uses red blood cell (RBC)-based perfusates, with associated challenges, including free haem-driven ferroptotic tubular injury. Acellular perfusates avoid these risks. Subnormothermic machine perfusion (SMP, 32°C) may reduce metabolic demands while preserving organ viability, but the effect of perfusate type under these conditions remains unclear. In a paired experimental design, kidneys from eight deceased donors were randomized 1:1 to 6 hours of SMP with RBC-based (RBC-SMP) or acellular perfusate (SNAP), followed by 4 hours of RBC-based NMP (37°C) to simulate reperfusion. Upregulation of transcriptomic ischaemia-reperfusion injury (IRI) related pathways and downregulation of oxidative phosphorylation at 6 hours SMP and 4 hours reperfusion were similar between RBC-SMP and SNAP kidneys. No differences were observed between groups in transcriptional profiles, metabolic pathway scores, urinary tubular injury biomarker concentrations, or histology. We integrated publicly available NMP transcriptomic data for comparison, demonstrating that compared to 6 hours RBC-NMP at 37°C, both SMP groups showed equivalent pro-inflammatory pathway activation and oxidative phosphorylation depletion. Thus, we provide evidence that SNAP maintains kidneys with equivalent transcriptional and urinary tubular injury biomarker profiles to RBC-SMP. These findings support the feasibility of SNAP for clinical translation in future studies.
Open AccessA comparative analysis of acellular versus red cell based subnormothermic machine perfusion in human kidney transplantation
Normothermic machine perfusion (NMP) typically uses red blood cell (RBC)-based perfusates, with associated challenges, including free haem-driven ferroptotic tubular injury. Acellular perfusates avoid these risks. Subnormothermic machine perfusion (SMP, 32°C) may reduce metabolic demands while preserving organ viability, but the effect of perfusate type under these conditions remains unclear. In a paired experimental design, kidneys from eight deceased donors were randomized 1:1 to 6 hours of SMP with RBC-based (RBC-SMP) or acellular perfusate (SNAP), followed by 4 hours of RBC-based NMP (37°C) to simulate reperfusion. Upregulation of transcriptomic ischaemia-reperfusion injury (IRI) related pathways and downregulation of oxidative phosphorylation at 6 hours SMP and 4 hours reperfusion were similar between RBC-SMP and SNAP kidneys. No differences were observed between groups in transcriptional profiles, metabolic pathway scores, urinary tubular injury biomarker concentrations, or histology. We integrated publicly available NMP transcriptomic data for comparison, demonstrating that compared to 6 hours RBC-NMP at 37°C, both SMP groups showed equivalent pro-inflammatory pathway activation and oxidative phosphorylation depletion. Thus, we provide evidence that SNAP maintains kidneys with equivalent transcriptional and urinary tubular injury biomarker profiles to RBC-SMP. These findings support the feasibility of SNAP for clinical translation in future studies.
- Open Access
- 3 July 2025
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 112 (7)
Subnormothermic acellular machine perfusion for prolonged preservation of human kidneys
- 3 July 2025
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 112 (7)
Open AccessSubnormothermic acellular machine perfusion for prolonged preservation of human kidneys
- Open Access
- 30 March 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-14
Enzymatic conversion of human blood group A kidneys to universal blood group O
ABO blood group compatibility restrictions present the first barrier to donor-recipient matching in kidney transplantation. Here, we present the use of two enzymes, FpGalNAc deacetylase and FpGalactosaminidase, from the bacterium Flavonifractor plautii to enzymatically convert blood group A antigens from the renal vasculature of human kidneys to ‘universal’ O-type. Using normothermic machine perfusion (NMP) and hypothermic machine perfusion (HMP) strategies, we demonstrate blood group A antigen loss of approximately 80% in as little as 2 h NMP and HMP. Furthermore, we show that treated kidneys do not bind circulating anti-A antibodies in an ex vivo model of ABO-incompatible transplantation and do not activate the classical complement pathway. This strategy presents a solution to the donor organ shortage crisis with the potential for direct clinical translation to reduce waiting times for patients with end stage renal disease.
- 30 March 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-14
Open AccessEnzymatic conversion of human blood group A kidneys to universal blood group O
ABO blood group compatibility restrictions present the first barrier to donor-recipient matching in kidney transplantation. Here, we present the use of two enzymes, FpGalNAc deacetylase and FpGalactosaminidase, from the bacterium Flavonifractor plautii to enzymatically convert blood group A antigens from the renal vasculature of human kidneys to ‘universal’ O-type. Using normothermic machine perfusion (NMP) and hypothermic machine perfusion (HMP) strategies, we demonstrate blood group A antigen loss of approximately 80% in as little as 2 h NMP and HMP. Furthermore, we show that treated kidneys do not bind circulating anti-A antibodies in an ex vivo model of ABO-incompatible transplantation and do not activate the classical complement pathway. This strategy presents a solution to the donor organ shortage crisis with the potential for direct clinical translation to reduce waiting times for patients with end stage renal disease.
- Open Access
- 7 January 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (2) , 165-170
Honoring the gift: The transformative potential of transplant-declined human organs
- 7 January 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (2) , 165-170
Open AccessHonoring the gift: The transformative potential of transplant-declined human organs
- Open Access
- 27 August 2022
- Published by Springer Nature in Current Transplantation Reports
- Vol. 9 (4) , 308-317
Normothermic Machine Perfusion in Renal Transplantation
Purpose of Review: Normothermic machine perfusion (NMP) is a promising new tool in kidney transplantation to improve the outcome of marginal donor kidney transplantation. This review examines the current evidence for NMP in clinical practice and considers how the technology may be used in the future. Recent Findings and Summary: There is emerging evidence to suggest that NMP has the potential to expand the donor pool of transplantable organs. The safety and feasibility of NMP have been established in a number of clinical studies but more research is needed to optimise the perfusion conditions. NMP shows promise as a viability assessment tool with particular focus on biomarkers and imaging techniques which provide real-time information to facilitate transplantation decision-making. Moreover, the exciting development of new potential therapeutics such as cell and gene-based therapies which are deliverable during NMP may also improve and recondition grafts prior to implantation.
- 27 August 2022
- Published by Springer Nature in Current Transplantation Reports
- Vol. 9 (4) , 308-317
Open AccessNormothermic Machine Perfusion in Renal Transplantation
Purpose of Review: Normothermic machine perfusion (NMP) is a promising new tool in kidney transplantation to improve the outcome of marginal donor kidney transplantation. This review examines the current evidence for NMP in clinical practice and considers how the technology may be used in the future. Recent Findings and Summary: There is emerging evidence to suggest that NMP has the potential to expand the donor pool of transplantable organs. The safety and feasibility of NMP have been established in a number of clinical studies but more research is needed to optimise the perfusion conditions. NMP shows promise as a viability assessment tool with particular focus on biomarkers and imaging techniques which provide real-time information to facilitate transplantation decision-making. Moreover, the exciting development of new potential therapeutics such as cell and gene-based therapies which are deliverable during NMP may also improve and recondition grafts prior to implantation.
- Open Access
- 1 August 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (12) , 2791-2803
De novo SIX2 activation in human kidneys treated with neonatal kidney stem/progenitor cells
- 1 August 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (12) , 2791-2803
Open AccessDe novo SIX2 activation in human kidneys treated with neonatal kidney stem/progenitor cells
- Open Access
- 17 November 2021
- Published by MDPI AG in Transplantology
- Vol. 2 (4) , 460-477
Advances in Hypothermic and Normothermic Perfusion in Kidney Transplantation
Hypothermic and normothermic machine perfusion in kidney transplantation are purported to exert a beneficial effect on post-transplant outcomes compared to the traditionally used method of static cold storage. Kidney perfusion techniques provide a window for organ reconditioning and quality assessment. However, how best to deliver these preservation methods or improve organ quality has not yet been conclusively defined. This review summarises the promising advances in machine perfusion science in recent years, which have the potential to further improve early graft function and prolong graft survival.
- 17 November 2021
- Published by MDPI AG in Transplantology
- Vol. 2 (4) , 460-477
Open AccessAdvances in Hypothermic and Normothermic Perfusion in Kidney Transplantation
Hypothermic and normothermic machine perfusion in kidney transplantation are purported to exert a beneficial effect on post-transplant outcomes compared to the traditionally used method of static cold storage. Kidney perfusion techniques provide a window for organ reconditioning and quality assessment. However, how best to deliver these preservation methods or improve organ quality has not yet been conclusively defined. This review summarises the promising advances in machine perfusion science in recent years, which have the potential to further improve early graft function and prolong graft survival.
- Open Access
- 8 May 2021
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 108 (9) , 1072-1081
Mitochondria-targeted antioxidant MitoQ ameliorates ischaemia–reperfusion injury in kidney transplantation models
Ischaemia-reperfusion (IR) injury makes a major contribution to graft damage during kidney transplantation. Oxidative damage to mitochondria is an early event in IR injury. Therefore, the uptake, safety, and efficacy of the mitochondria-targeted antioxidant MitoQ were investigated in models of transplant IR injury. MitoQ uptake by warm and cooled pairs of pig and declined human kidneys was measured when preserved in cold static storage or by hypothermic machine perfusion. Pairs of pigs’ kidneys were exposed to defined periods of warm and cold ischaemia, flushed and stored at 4°C with or without MitoQ (50 nmol/l to 250 µmol/l), followed by reperfusion with oxygenated autologous blood in an ex vivo normothermic perfusion (EVNP). Pairs of declined human kidneys were flushed and stored with or without MitoQ (5–100 µmol/l) at 4°C for 6 h and underwent EVNP with ABO group-matched blood. Stable and concentration-dependent uptake of MitoQ was demonstrated for up to 24 h in pig and human kidneys. Total blood flow and urine output were significantly greater in pig kidneys treated with 50 µmol/l MitoQ compared with controls (P = 0.006 and P = 0.007 respectively). In proof-of-concept experiments, blood flow after 1 h of EVNP was significantly greater in human kidneys treated with 50 µmol/l MitoQ than in controls (P ≤ 0.001). Total urine output was numerically higher in the 50-µmol/l MitoQ group compared with the control, but the difference did not reach statistical significance (P = 0.054). Mitochondria-targeted antioxidant MitoQ can be administered to ischaemic kidneys simply and effectively during cold storage, and may improve outcomes after transplantation.
- 8 May 2021
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 108 (9) , 1072-1081
Open AccessMitochondria-targeted antioxidant MitoQ ameliorates ischaemia–reperfusion injury in kidney transplantation models
Ischaemia-reperfusion (IR) injury makes a major contribution to graft damage during kidney transplantation. Oxidative damage to mitochondria is an early event in IR injury. Therefore, the uptake, safety, and efficacy of the mitochondria-targeted antioxidant MitoQ were investigated in models of transplant IR injury. MitoQ uptake by warm and cooled pairs of pig and declined human kidneys was measured when preserved in cold static storage or by hypothermic machine perfusion. Pairs of pigs’ kidneys were exposed to defined periods of warm and cold ischaemia, flushed and stored at 4°C with or without MitoQ (50 nmol/l to 250 µmol/l), followed by reperfusion with oxygenated autologous blood in an ex vivo normothermic perfusion (EVNP). Pairs of declined human kidneys were flushed and stored with or without MitoQ (5–100 µmol/l) at 4°C for 6 h and underwent EVNP with ABO group-matched blood. Stable and concentration-dependent uptake of MitoQ was demonstrated for up to 24 h in pig and human kidneys. Total blood flow and urine output were significantly greater in pig kidneys treated with 50 µmol/l MitoQ compared with controls (P = 0.006 and P = 0.007 respectively). In proof-of-concept experiments, blood flow after 1 h of EVNP was significantly greater in human kidneys treated with 50 µmol/l MitoQ than in controls (P ≤ 0.001). Total urine output was numerically higher in the 50-µmol/l MitoQ group compared with the control, but the difference did not reach statistical significance (P = 0.054). Mitochondria-targeted antioxidant MitoQ can be administered to ischaemic kidneys simply and effectively during cold storage, and may improve outcomes after transplantation.